

INVITED EDITORIAL

H. G. van der Poel · J. A. Witjes · J. A. Schalken
F. M. J. Debruyne

Automated image analysis for bladder cancer

Received: 22 May 1996 / Accepted: 11 August 1997

Abstract The genetic and epigenetic changes that occur during cancer development result in apparent morphological changes. Light microscopic image analysis provides objective assessment of cellular and nuclear morphology. The complexity of changes reflects the basic nature of dedifferentiation: a multi-hit process. Image analysis methods proved valuable for the assessment of malignancy in bladder cancer. Clinically applicable systems have been developed to diagnose urothelial cell cancer and predict prognosis. What is the place of these systems in daily practice?

Key words Image analysis · Bladder cancer · Morphometry · Karyometry · DNA ploidy

Introduction

The biology of tumour development is characterized by many morphological cellular and nuclear changes. These changes can be detected using light microscopy. Study of these changes in benign and malignant tissue showed typical differences that are widely used for the grading of cancer. The causes of the morphological changes are ill-understood. Both genetic and epigenetic factors influence cell morphology. This explains the correlation between morphological changes and cell behaviour as is found in malignant dedifferentiation.

The low reproducibility of both cytological [37] and histological [33] grading systems for bladder cancer illustrates the need for objectivation of the morphological changes. Here we will review the literature on the causes of the morphological cellular and nuclear changes.

Moreover, the development and use of image analysis systems for quantitation of these changes is discussed.

Nuclear matrix and nuclear morphology

In 1974, Berezny and Coffey [3] observed disruption of nuclear structure of isolated rat liver nuclei by mild digestion with proteases, whereas other chemical treatments had no influence on nuclear morphology. Removing chromatin, DNA, RNA and phospholipids from the nucleus, they found a spherical residual particle consisting of more than 98% polypeptides and accounting for less than 15% of the mass of an entire cell nucleus. The major function of this nuclear matrix is organization of the DNA into loop domains. By topoisomerase II activity in the matrix it modulates DNA topology. Moreover, it plays a role in RNA synthesis by association of the transcribed genes to the matrix and binding RNA processing intermediates [19, 20, 34, 35]. The mechanism by which the nuclear matrix structures nuclear shape is called tensegrity. This is defined as a dynamic structure based on a framework composed of compression elements and tension cables [35].

The nuclear matrix has been shown to be cell type specific [19, 20]. Moreover extracellular factors determine the composition and morphology of the nuclear matrix [21, 34, 35]. Recent studies have shown differences in nuclear matrix protein composition in transitional cell cancer compared with normal bladder mucosa, illustrating the role of the nuclear matrix in tumour development [30].

The nuclear matrix determines nuclear morphology and regulates gene expression. Mulder et al. [31] described the genetic changes in colorectal cancer and correlated these changes with nuclear morphology. The nuclear shape and chromatin pattern features established in light microscopic images were predominantly associated with tumour progression in colon carcinoma and were not influenced by the individual molecular genetic alterations such as allelic deletions in chromo-

H. G. van der Poel (✉) · J. A. Witjes · J. A. Schalken
F. M. J. Debruyne
Department of Urology, University Hospital, P.O. Box 9101,
6500 HB Nijmegen, The Netherlands
Tel: (+31) 024-3613920, fax: (+31) 024-3541031,
e-mail: h.vanderpoel@uro.azn.nl

somes 5q, 18p, 17p, and mutations in the *ras* gene. Nuclear chromatin texture, however, was inversely correlated with fractional allelic loss, a measure of overall genetic changes in the cell. Moreover, for urothelium it was shown that extracellular components influence nuclear matrix organization and in this way may regulate the epithelium [21]. These findings suggest that, in normal as well as cancerous tissue, genetic and epigenetic changes determine nuclear morphology. Hence, nuclear morphology could be applied to monitor the overall genetic and epigenetic changes in tumour development.

Image analysis techniques

Image analysis systems are composed of a light or fluorescence microscope and a charge-coupled device (CCD) camera for image acquisition. Image processing and analysis are performed on a (personal) computer with a framegrabber board. The microscope can be equipped with an automated cross table for computer-directed selection of areas of interest. Moreover, autofocus methods can be applied. Several of these systems have been tested and are commercially available. Only a few systems, however, provide built-in routines for daily use. Standardization and data recording and presentation determine the value of the system and should be thoroughly tested before the method can be of value for daily practice.

Using different staining techniques, objects of interest can be differentiated. The Feulgen-Schiff staining method is used for analysis of nuclear morphology and chromatin analysis [18]. Since DNA is stained in this method it is also well suited for analysis of nuclear DNA content. Furthermore, in situ hybridization methods and immunostaining can be quantified by image analysis techniques [10]. In this review nuclear morphological analysis by image analysis in transitional cell carcinoma of the bladder will be discussed on the basis of recent literature. Earlier studies have been reviewed elsewhere [45].

Cytology

The criteria for routine cytological grading have recently been reviewed [32]. Both cells in urine and bladder washings can be graded, although superior results from bladder washings have been reported. Automated grading using image analysis has been extensively studied. Between 1975 and 1989 several publications appeared from the Montefiori Medical Center in New York on computer image analysis of voided urine cytology [25, 38]. A system was constructed for the automatic grading of urinary cytology based on the cell-to-cell reference of a panel of observers. Sensitivity of the system was 84% for the detection of urothelial cell carcinoma, as compared with 63% for visual cytology of the same cases [38]. A special algorithm reduced the number of cells necessary for analysis.

In another study the analysis of 32 nuclear features in bladder wash material from patients with superficial bladder cancer was tested and nuclear shape and the 2c deviation index [7] were found to correlate with tumour grading [44, 46]. This quantitative cytology system (Quanticyt) was tested in a study population of 1412 patients, bladder wash samples being divided into low, intermediate and high risk on the basis of the karyometric analysis. The system is now commercially available.

Analogous to the system described by Koss et al. [25, 38] the Quanticyt system automatically analyses nuclei in light microscopic images. In contrast to the system of Koss et al., the Quanticyt system used the histological findings and follow-up data (tumour recurrence and progression) as reference, instead of cytology grading. Moreover, bladder wash samples were applied instead of voided urine. When compared with expert cytology the sensitivity of automated cytology systems was equally good (unpublished data).

Recently Veltri et al. [49] showed that a combination of cellular and nuclear features predicted tumour recurrences more accurately than routine cytology.

Several disadvantages of automated cytology still exist. Although sensitivity for low-grade lesions is superior for automated systems compared with visual cytology, many papillary lesions will still not be detected. Hence, cystoscopy is still required to confirm the presence of small papillary lesions in patients suspected of having bladder tumours. Future studies should be directed to the issue of predicting progression rather than recurrence. Low-grade papillary lesions may be left unresected for a period of time without increasing the risk of progression. Another issue consists of the application of automated microscopy in daily practice. Although a report is generated it still has to be incorporated in clinical use and, ultimately, influence clinical decision making. Prospective evaluation comparing different tumour markers in cytology is required to determine whether markers will influence cystoscopy frequency and timing.

The application of image analysis methods to the assessment of antibody staining techniques specific to bladder tumours has been studied [8]. The role of image analysis can only be as important as the sensitivity of the antibody used. In the context of this article it should be stated that image analysis methods will be important in the accurate assessment of the distribution and location of staining when tumour markers are applied.

DNA ploidy analysis

Earlier flow cytometry studies found increased aneuploidy in malignant cell populations [43]. Bass et al. [2, 4, 8, 23] developed a fluorescence method for ploidy analysis in bladder cytology. Shackney et al. [36] found a correlation of ploidy and S-phase fraction changes with tumour behaviour and therapy resistance in bladder cancer. When compared with flow cytometry, image

cytometry in histological sections proved to be more sensitive for small populations of aneuploid cells [13]. Although of additional prognostic value to grade and stage [41] in histological material, flow cytometry analysis was never used extensively in daily practice. The need for tissue disaggregation makes the method too elaborative for daily use. Moreover, when other features were compared with DNA flow cytometry, the predictive value dropped [5] and was found to be of no clinical use in pTa-pT1 tumours [42].

In cytological material image cytometry and flow cytometry proved equivalent for the detection of aneuploidy [11]. DNA ploidy analysis in addition to routine cytology improved sensitivity up to 84% [1]. De Vere White and Deitch [17] reviewed the use of flow cytometry in bladder cancer and concluded that the method is particularly useful for monitoring the condition of the mucosa and predicting tumour recurrence.

Hence, the use of DNA ploidy assessment is probably only of value for bladder cancer in cytological material. The simultaneous morphometric evaluation when image cytometry is applied is an advantage of this method. Currently, several systems are available for the determination of DNA ploidy in urine or bladder wash material.

Histology

Several multivariate studies have been published on histological automated tumour grading. Blomjous et al. [6] proposed an interactive nuclear selection system for the histological grading of bladder cancer: a mean value over 95 μm^2 of the largest selected nuclei was correlated with an increased progression rate. In Ta-T1 low-grade cancers, however, Lipponen et al. [29] found the mean nuclear size of the ten largest selected nuclei only of predictive value in combination with the mitotic/volume index, indicating that proliferation rather than nuclear size was of predictive value [27, 28]. Sowter et al. [39, 40] proposed a grading system based on both subjective histological grading and nuclear size analysis, whereas Borland et al. [9] found nuclear shape useful for predicting progression after cystectomy.

De Meester et al. [16] developed a system for the automated grading of histological bladder tumour material including assessment of tissue architectural features. The system, however, was sensitive to the area selected and was not tested against clinical outcome. Lipponen et al. [28] suggested D_{max} , the longest nuclear axis, as a prognostic clinical marker in pTa-pT1 papillary bladder cancer. A comparable multivariate analysis on histological material was performed by Colombel et al. [14, 15]. Again a combination of several nuclear features resulted in prognostic information regarding tumour recurrence and progression of superficial as well as invasive tumours [14]. They advocated the use of their system mainly in superficial cancers.

A different approach to histological grading was applied by van Velthoven et al. [48]. Instead of using

histological sections, pronase-digested, resuspended material was used. The chromatin pattern of each Feulgen-stained nucleus was quantified. In combination with ploidy analysis this yielded a 91% correct prediction of tumour recurrence. Similar evidence of the value of chromatin pattern characterization for the grading of tumours was provided by Choi et al. [12]. Before widespread clinical application is feasible, however, study is needed to determine the influence of digestion techniques on chromatin patterns.


In summary, early studies focused on nuclear size as a prognostic marker. When more sophisticated systems came available the complexity of morphological features increased. Multivariate analysis showed that a combination of nuclear shape and chromatin features probably adds to clinical findings. Although all these studies support the value of quantitative analysis methods for interpretation of microscopic images, none compared the method with a range of other markers. Hence, before imaging methods become of clinical value, studies comparing different prognosticators are required. However, these methods can already support pathological diagnosis. In particular reproducibility increases using quantitative methods. Moreover, cell-to-cell analysis of, for example, DNA ploidy may aid in more accurate (sub)grading of, for example, of grade 2 tumours.

Follow-up of bladder cancer patients

Several clinical factors predict the chance of tumour recurrence. Multiplicity, tumour grade and stage, and earlier tumour recurrence rate are correlated with tumour recurrences despite intravesical instillation treatment [24, 26]. Hall et al. [22] proposed a follow-up plan based on multiplicity and recurrence at 3 months after resection – two indicators of increased recurrence rate. Hence, available clinical data can aid in the planning of follow-up schemes. Cystoscopy remains the gold standard in the detection of tumour recurrences. A reliable marker on cytological material could reduce cystoscopy frequency in patients with a low risk for tumour recurrence and thus reduce costs and patient inconvenience. Moreover, predicting tumour recurrences more reliably can aid in the stratification for (intravesical) treatment modalities.

In a low-risk group of patients as defined by Kurth et al. [26], still 7% of tumours progressed to invasive disease within 3 years of diagnosis and this group comprised 52% of their patient population, whereas the high-risk group comprised only 6.7% of the patients, of whom 42% progressed. Hence the absolute number of progressive tumours in the low-risk group is still higher than the absolute number in the high-risk group. These data indicate that changing treatment and follow-up schemes based on relative risk alone underestimates the potential risk of the less aggressive but more frequent cancers and may put an equal number of patients at risk of late detection of progression as is found in time by

Fig. 1 The place of automated image analysis in the follow-up of patients with bladder cancer. *TURT* transurethral resection of tumour



meticulous follow-up of the high-risk patient group. Two factors are important to overcome this dilemma: more accurate prognostic markers and a reliable tool for the monitoring of bladder mucosal changes during patient follow-up, in particular in the less progressive cancers.

Follow-up schemes and automated image analysis

Since the majority of patients who experience tumour recurrences do so within 2 years after transurethral resection of a tumour, cystoscopy is traditionally recommended to be performed every 3 or 4 months for the first 1–2 years. The chance of developing tumour progression due to later detection and thus resection of tumour recurrences is not known. Moreover, tumour characteristics seem to change over time, making prediction of tumour behaviour in an early phase of disease more difficult [47].

A clear report is mandatory for clinical integration of automated imaging systems. A high frequency of follow-up cystoscopies may not be necessary in large groups of “low-risk” patients. The presence of small lesions of low malignancy grade may be efficiently treated expectantly or with laser coagulation. In these cases information on malignancy grade of the bladder mucosa and the lesions present can be provided by automated image analysis supported cytology. Figure 1 shows a possible treatment protocol in which image analysis is applied for decision-making in (1) treatment after transurethral tumour resection and (2) follow-up schemes.

Automated image analysis is easily accessible for daily practice. Urologists acquainted with markers such as DNA ploidy and morphology can apply the method to support decision-making. Only with effective collaboration of urologists and pathologists will new methods find their way into daily practice to optimize clinical decision making.

References

1. Amberson JB, Laino JP (1993) Image cytometric deoxyribonucleic acid analysis of urine specimens as an adjunct to visual cytology in the detection of urothelial cell carcinoma. *J Urol* 149:42
2. Bass RA, Hemstreet GP, Honker NA, Hurst RE, Doggett RS (1987) DNA cytometry and cytology by quantitative fluorescent image analysis in symptomatic bladder cancer patients. *Int J Cancer* 40:698
3. Berezny R, Coffey DS (1974) Identification of a nuclear protein matrix. *Biochem Biophys Res Commun* 60:1410
4. Bi W, Rao JY, Hemstreet GP, Fang P, Asal NR, Zang M, Min KW, Ma Z, Lee E, Li G (1993) Field molecular epidemiology: feasibility of monitoring for the malignant bladder cell phenotype in a benzidine-exposed occupational cohort. *J Occup Med* 35:20
5. Bittard H, Lamy B, Billery C (1996) Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. *J Urol* 155:1887
6. Blomjous CEM, Vos W, Schipper NW, Uytendinck AM, Baak JPA, de Voogt HJ, Meijer CJLM (1990) The prognostic significance of selective nuclear morphometry in urinary bladder carcinoma. *Hum Pathol* 21:409
7. Böcking A, Adler CP, Common HD, Hilgarth M, Granzen B, Auffermann W (1984) Algorithm for a DNA cytophotometric diagnosis and grading of malignancy. *Anal Quant Cytol* 6:1
8. Bonner RB, Hemstreet GP, Fradet Y, Rao JY, Min KW, Hurst RE (1993) Bladder cancer risk assessment with quantitative fluorescence image analysis of tumour markers in exfoliated bladder cells. *Cancer* 72:2461
9. Borland RN, Partin AW, Epstein JI, Brendler CB (1993) The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. *J Urol* 149:272
10. Cajulis RS, Haines GK, Frias-Hidvegi D, McVary K, Bacus JW (1995) Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washings: a comparative study. *Diagn Cytopathol* 13:214
11. Chabanas A, Rambeaud JJ, Seigneurin D, Fradet Y, Lawrence JJ, Faure G (1993) Flow and image cytometry for DNA analysis in bladder washings: improved concordance by using internal reference for flow. *Cytometry* 14:943
12. Choi HK, Vasko J, Bengtsson E, Jarkans T, Malmström PU, Wester K, Busch P (1994) Grading of transitional cell bladder carcinoma by texture analysis of histological sections. *Ann Cell Pathol* 6:327

13. Clemo FA, Crabtree WN, Walker E, DeNicola DB (1993) Comparison of image analysis and flow cytometric measurements of DNA content of canine transitional cell carcinomas. *Anal Quant Cytol Histol* 15:418
14. Colombel M, de Launoit Y, Bellot J, Kiss R, Abbou C, Chopin D (1995) Prognostic evaluation of morphonuclear parameters in superficial and invasive bladder cancer. *Br J Urol* 75:364
15. Colombel MC, Pous MF, Abbou CC, VanVelthoven R, Bellot J, Spyrtas F, Andrieu C, de Launoit Y, Chopin DK (1994) Computer assisted image analysis of bladder tumour nuclei for morphonuclear and ploidy assessment. *Anal Cell Pathol* 6:137
16. de Meester U, Young IT, Lindeman J, van der Linden HC (1991) Towards a quantitative grading of bladder tumours. *Cytometry* 12:602
17. deVere White RW, Deitch AD (1992) Evaluation of flow cytometry as a screening test for bladder cancer *J Cell Biochem Suppl* 161:80
18. Feulgen R, Rossenbeck M (1924) Mikroskopisch-chemischer Nachweis einer Nucleinsäure vom Typhus der Thymonucleinsäure und die darauf beruhende elektive Färbung von Zellkernen in mikroskopische Präparaten. *Hoppe Seylers Z Physiol Chem* 135:203
19. Fey EG, Penman S (1988) Nuclear matrix proteins reflect cell type of origin in cultured human cells. *Proc Natl Acad Sci USA* 85:121
20. Getzenberg RH (1994) Nuclear matrix and the regulation of gene expression: tissue specificity. *J Cell Biochem* 55:22
21. Gordon JN, Shu WP, Schluskel RN, Droller MJ, Liu BC (1993) Altered extracellular matrices influence cellular processes and nuclear matrix organization of overlying human bladder urothelial cells. *Cancer Res* 53:4971
22. Hall RR, Parmar MKB, Richards AB, Smith PH (1994) The cystoscopic follow-up of patients with Ta.T1 bladder carcinoma and the role of adjuvant intravesical therapy: a proposal. *BMJ* 308:257
23. Hemstreet GP, Rollins S, Jones P, Rao JY, Hurst RE, Bonner RB, Hewett-Smith BG (1991) Identification of a high-risk subgroup of grade 1 transitional cell carcinoma using image analysis based deoxyribonucleic acid ploidy analysis of tumor tissue. *J Urol* 146:1525
24. Kiemeny LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FMJ (1993) Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. *J Urol* 150:60
25. Koss LG, Bartels PH, Wied GL (1980) Computer-based diagnostic analysis of cells in the urinary sediment. *J Urol* 123:846
26. Kurth KH, Denis L, Bouffloux C, Sylvester R, Debruyne FMJ, Pavone-Macaluso M, Oosterlinck W (1995) Factors affecting recurrence and progression in superficial bladder tumours. *Eur J Cancer* 31:1840
27. Lipponen PK (1993) Stereologically measured nuclear volume in comparison to two-dimensional nuclear morphometry, mitotic index and flow cytometry in predicting disease outcome in bladder cancer. *Anticancer Res* 13:529
28. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R, Haapasalo H (1992) Prediction of superficial bladder cancer by nuclear image analysis. *Eur J Cancer* 29:61
29. Lipponen PK, Eskelinen MJ, Sotarauto M (1991) Prediction of Ta-I G1-2 transitional cell bladder cancer: evaluation by histoquantitative methods. *Scand J Urol Nephrol* 25:129
30. Miyanaga N, Akaza H, Ohtani M, Takeshima H, Koiso K, Takahashi T, Uemura M (1995) Nuclear matrix proteins as a urine marker for transitional cell carcinoma of the bladder: a preliminary report. *J Urol* 153:457A
31. Mulder JW, Offerhuus GJ, de Feyter EP, Floyd JJ, Kern SE, Vogelstein B, Hamilton SR (1992) The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. *Am J Pathol* 141:797
32. Murphy WM (1997) Current issues in pathology of superficial bladder cancer. In: Pagnano F, Fair WR (eds) *Superficial bladder cancer*. ISIS Medical Media, Oxford
33. Ooms ECM, Anderson WAD, Alons CL, Boon ME, Veldhuizen RW (1983) Analysis of the performance of pathologists in the grading of bladder tumours. *Hum Pathol* 14:140
34. Pienta KJ, Murphy BC, Getzenberg R, Coffey DS (1991) The effect of extracellular matrix interactions on morphologic transformation in vitro. *Biochem Biophys Res Commun* 179:333
35. Pienta KJ, Partin AW, Coffey DS (1989) Cancer as a disease of DNA organization and dynamic cell structure. *Cancer Res* 49:2525
36. Shackney SE, Berg G, Simon SR, Cohen J, Amina S, Pommersheim W, Yakulis R, Wang S, Uhl M, Smith CA, et al (1995) Origins and clinical implications of aneuploidy in early bladder cancer. *Cytometry* 22:307
37. Sherman AB, Koss LG, Adams SE (1984) Interobserver and intraobserver differences in the diagnosis of urothelial cells: comparison with classification by computer. *Anal Quant Cytol Histol* 6:112
38. Sherman AB, Koss LG, Wyschogrod D, Melder KH, Eppich EM, Bales CE (1986) Bladder cancer diagnosis by computer image analysis of cells in the sediment of voided urine using a video scanning system. *Anal Quant Cytol Histol* 8:177
39. Sowter C, Slavin G, Sowter G, Rosen D, Hendry W (1991) Morphometry of bladder carcinoma: morphometry and grading complement each other. *Anal Cell Pathol* 3:1
40. Sowter C, Sowter G, Slavon G, Rosen D (1990) Morphometry of bladder carcinoma: definition of a new variable. *Anal Cell Pathol* 2:205
41. Tachibana M, Deguchi N, Baba S, Jitsukawa S, Hata M, Tazaki H (1993) Prognostic significance of bromodeoxyuridine high labeled bladder cancer measured by flow cytometry: does flow cytometric determination predict the prognosis of patients with transitional cell carcinoma of the bladder? *J Urol* 149:739
42. Tetu B, Allard P, Fradet Y, Roberge N, Bernard P (1996) Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer. *Hum Pathol* 27:922
43. Tribukait B, Gustafson H, Esposti PL (1982) The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumors: a study of 100 untreated cases. *J Urol* 54:130
44. van der Poel HG, Oosterhof GON, Schaafsma HE, Wiersma-v. Tilburg A, Debruyne FMJ, Schalken JA (1992) Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladder. In: Schröder FH (ed) *Recent progress in bladder and kidney cancer (EORTC genitourinary group monograph 11)*, p 9
45. van der Poel HG, Schaafsma HE, Vooijs G, Debruyne FMJ, Schalken JA (1992) Quantitative light microscopy in urologic oncology. *J Urol* 148:1
46. van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, Schalken JA (1996) Quanticyt: karyometric analysis of bladder washings for patients with superficial bladder cancer. *Urology* 48:357
47. van der Poel HG, van Cauberghe RD, Boon ME, Debruyne FMJ, Schalken JA (1992) Karyometry in recurrent superficial transitional cell tumors of the bladder. *Urol Res* 20:375
48. van Velthoven R, Petein M, Oosterlinck WJ, Roels H, Pasteels JL, Schulman C, Kiss R (1995) The use of digital image analysis of chromatin texture in Feulgen-stained nuclei to predict recurrence of low grade superficial transitional cell carcinoma of the bladder. *Cancer* 75:560
49. Veltri RW, Miller MC, Slaton JW, Dinney CPN, Liebert M, Grossman HB, O'Dowd JW (1997) Computer-assisted quantitative nuclear grading (QNG) can predict bladder cancer recurrence using bladder cancer cytology samples. *J Urol* 157 [Suppl]:342